Galderma Group Valuation
| GALD Stock | 154.20 0.40 0.26% |
At this time, the firm appears to be fairly valued. Galderma Group N retains a regular Real Value of USD154.72 per share. The prevalent price of the firm is USD154.2. Our model calculates the value of Galderma Group N from evaluating the firm fundamentals such as Return On Equity of 0.0492, current valuation of 37.25 B, and Return On Asset of 0.0367 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Galderma Group's valuation include:
Price Book 5.9527 | Enterprise Value | Enterprise Value Ebitda 47.9184 | Price Sales 7.8056 | Forward PE 43.29 |
Fairly Valued
Today
Please note that Galderma Group's price fluctuation is very steady at this time. Calculation of the real value of Galderma Group N is based on 3 months time horizon. Increasing Galderma Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Galderma stock is determined by what a typical buyer is willing to pay for full or partial control of Galderma Group N. Since Galderma Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Galderma Stock. However, Galderma Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 154.2 | Real 154.72 | Hype 153.97 | Naive 159.55 |
The intrinsic value of Galderma Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Galderma Group's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Galderma Group N helps investors to forecast how Galderma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Galderma Group more accurately as focusing exclusively on Galderma Group's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Galderma Group's intrinsic value based on its ongoing forecasts of Galderma Group's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Galderma Group's closest peers.
Galderma Group Cash |
|
Galderma Group Total Value Analysis
Galderma Group N is currently anticipated to have takeover price of 37.25 B with market capitalization of 36.61 B, debt of 2.76 B, and cash on hands of 175 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Galderma Group fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
37.25 B | 36.61 B | 2.76 B | 175 M |
Galderma Group Investor Information
About 36.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.91. Galderma Group N last dividend was issued on the 25th of April 2025. Based on the analysis of Galderma Group's profitability, liquidity, and operating efficiency, Galderma Group N is doing better financially today then in previous quarter. It has a moderate chance of reporting better financial numbers in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.096 | 0.13 |
|
| |||||
| Total Cash From Operating Activities | 518.9 M | 494.2 M |
|
| |||||
| Operating Income | 492.4 M | 741.8 M |
|
|
Galderma Group Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Galderma Group has an asset utilization ratio of 35.19 percent. This indicates that the Company is making USD0.35 for each dollar of assets. An increasing asset utilization means that Galderma Group N is more efficient with each dollar of assets it utilizes for everyday operations.Galderma Group Profitability Analysis
Considering Galderma Group's profitability and operating efficiency indicators, Galderma Group N is yielding more profit at the present time then in previous quarter. It has a moderate chance of reporting better profitability numbers in March. Profitability indicators assess Galderma Group's ability to earn profits and add value for shareholders.Net Income | First Reported 2010-12-31 | Previous Quarter 265.6 M | Current Value 278.9 M | Quarterly Volatility 155.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.55 | 0.63 |
|
| |||||
| Operating Profit Margin | 0.096 | 0.13 |
|
|
For Galderma Group profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Galderma Group N to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Galderma Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Galderma Group's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Galderma Group over time as well as its relative position and ranking within its peers.
Galderma Group Earnings per Share Projection vs Actual
By analyzing Galderma Group's earnings estimates, investors can diagnose different trends across Galderma Group's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Galderma Group N is based on EPS before non-recurring items and includes expenses related to employee stock options.Galderma Group Ownership Allocation
Galderma Group N has a total of 234.82 Million outstanding shares. Galderma Group secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Galderma Group Profitability Analysis
The company reported the revenue of 4.44 B. Net Income was 231 M with profit before overhead, payroll, taxes, and interest of 3.25 B.About Galderma Group Valuation
Our relative valuation model uses a comparative analysis of Galderma Group. We calculate exposure to Galderma Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Galderma Group's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.5 B | 2.8 B | |
| Pretax Profit Margin | 0.06 | 0.07 | |
| Operating Profit Margin | 0.13 | 0.10 | |
| Net Profit Margin | 0.05 | 0.05 | |
| Gross Profit Margin | 0.63 | 0.55 |
Additional Tools for Galderma Stock Analysis
When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.